CD8A and ovarian carcinoma: ,130 Initially, the combination of CGX-1321 and DKN-01 (a DDK1 inhibitor) was not found to increase CD8+ T cell levels more significantly, but a subsequent study showed that DKN-01 increased HLA/MHC I expression in ovarian cancer tissues, which could increase their antigenicity and reduce immune escape.